$WUXI APPTEC(02359.HK) rose over five percentage points, $AKESO(09926.HK) rose over four percentage points. Hong Kong-listed innovative drug stocks and CXOs are strengthening together, driven by expectations around AI drug discovery and overseas expansion. $Eli Lilly(LLY.US), on the other hand, dipped slightly. The logic for large pharmaceutical companies is different from that of small-cap innovative drug stocks; they are more weighed down by competition in weight-loss drugs and valuation digestion.
Both are in the pharmaceutical sector, but Hong Kong-listed innovative drug stocks are rebounding, while US-listed large pharma companies are taking a breather. Given this US-HK divergence, should we follow the current momentum in Hong Kong stocks, or wait for large pharma valuations to come down for a more stable entry?
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
